Search filters

List of works by Kiran Naqvi

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

scientific article published on 15 November 2018

A potential role of ruxolitinib in leukemia

scientific article published on 03 June 2011

Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model ⬇️

scientific article published on May 2, 2011

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

scientific article published on 20 February 2018

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

scientific article published on 26 July 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

scientific article published on 06 November 2020

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

scientific article published on 5 August 2016

Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

scientific article published on 12 March 2019

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

scientific article

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

scientific article published on 01 February 2020

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

scientific article

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers ⬇️

scientific article published on August 25, 2011

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

scientific article published on 29 April 2019

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 25 September 2019

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

scientific article published on 30 July 2016

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

scientific article published on 16 June 2020

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

scientific article

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

scientific article published on 24 June 2019

Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

scientific article published on 01 October 2018

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

scientific article published on 11 August 2017

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

scientific article published on 12 November 2020

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Paulina is supported by:

About Paulina

Help